Scandinavian Tobacco Group (STG) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
23 Jan, 2026Executive summary
Q2 2024 net sales rose 6.3% to DKK 2,366 million, with 4.8% organic growth driven by next-generation products and handmade cigars; EBITDA margin recovered to 24.5% from 23.1% year-over-year.
Adjusted EPS increased to DKK 4.1 from DKK 3.5; free cash flow before acquisitions was DKK 177 million, up from DKK 159 million.
The Mac Baren acquisition (DKK 535 million, completed 1 July 2024) will add about 8% to group net sales annually, expanding the portfolio in smoking tobacco and nicotine pouches.
Growth Enablers now account for 12% of group net sales, with NGP at 6%.
A new commercial structure was implemented to enhance consumer focus, agility, and execution.
Financial highlights
Q2 2024 net sales: DKK 2,366 million (Q2 2023: DKK 2,225 million); H1 2024: DKK 4,314 million.
EBITDA before special items: DKK 580 million (Q2 2023: DKK 514 million); margin 24.5%.
Net profit: DKK 297 million (Q2 2023: DKK 304 million); Adjusted EPS: DKK 4.1 (Q2 2023: DKK 3.5).
Free cash flow before acquisitions: DKK 177 million (Q2 2023: DKK 159 million); ROIC: 10.5% (Q2 2023: 13.1%).
Gross margin stable at 46.9%; OpEx ratio improved to 23.0% from 23.8%.
Outlook and guidance
2024 guidance maintained: net sales DKK 8.8–9.1 billion, EBITDA margin 22–24%, free cash flow before acquisitions DKK 0.8–1.0 billion, adjusted EPS DKK 12.5–14.5.
Guidance excludes Mac Baren impact, to be updated with Q3 results.
Organic net sales of handmade cigars expected to grow; next-generation products to increase by over 50%.
Growth Enablers expected to account for about 10% of group net sales for the full year.
Second half expected to see net sales growth but lower EBITDA margin due to NGP expansion and strong Q3 2023 comparison.
Latest events from Scandinavian Tobacco Group
- Organic sales fell 8.8% in Q1 2025, prompting lower guidance amid US and FX headwinds.STG
Q1 202513 Mar 2026 - 2025 results declined, but Focus2030 and strong cash flow support a stable 2026 outlook.STG
Q4 20259 Mar 2026 - Focus2030 targets growth in cigars and nicotine pouches, efficiency, and flexible shareholder returns.STG
CMD 20253 Feb 2026 - Q3 net sales up 7.1% on Mac Baren deal; margin and organic growth declined.STG
Q3 202414 Jan 2026 - Net sales up 5.4% to DKK 9.2bn, but profit down 20.5% amid margin pressure and investments.STG
Q4 202426 Dec 2025 - Record sales, higher dividends, and all board proposals approved amid ongoing strategic investments.STG
AGM 202529 Nov 2025 - Q2 2025 saw flat sales, margin pressure, and guidance reaffirmed despite organic decline.STG
Q2 202523 Nov 2025 - Q3 2025 organic sales rose 0.3% with margin recovery and narrowed full-year guidance.STG
Q3 202512 Nov 2025